Lutikizumab

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A dual-variable domain (DVD) immunoglobulin G1 kappa (IgG1k) against the inflammatory cytokine human interleukin-1 alpha (IL-1a) and beta (IL-1b), with potential anti-inflammatory activity. Upon administration, lutikizumab targets, binds to, and neutralizes IL-1a/b thereby preventing the activity of IL-1a and IL-1b. This may inhibit IL1a/b-mediated inflammatory responses. This may reduce pain and slows tissue destruction and structural progression in diseases in which IL-1a/b are upregulated. IL1a/b, inflammatory mediators, play key roles in immune regulation and inflammatory processes.

**Synonyms:** - ABT 981 - ABT-981 - ABT981 - LUTIKIZUMAB